The Massachusetts Institute of Technology spinout has created a new class of activity sensors that query the body and report back clinically relevant information.
The studies involved data from 14,000 Hispanic women and showed the 87-SNP risk score outperformed its 86-SNP score for European women.
Glycotest's biomarker test for detection of hepatocellular carcinoma calculates the amount of monosaccharide fucose that appears abnormally on specific serum glycoproteins.
Cellworks' technology predicted drug resistance in newly diagnosed patients with myelodysplastic syndromes.
The UK developers believe that their device has the potential for multiplex testing at the point of care using solid-state nanopore sensing with DNA probes.
An Australian research group is developing a diagnostic test that uses an engineered toxin to detect an abnormal sugar in the blood of ovarian cancer patients.
Qorvo Biotechnologies and Novel Biomarkers Catalyst Lab are developing prototype cartridge-based HCV cAg assays for confirmatory testing.
A tick-borne disease working group recommends the federal government explore using new technologies and repurposing existing ones to improve diagnosis.
The nucleic acid diagnostic platform they are developing doesn't require expensive optics, and it could be available as a manufacturing prototype in about a year.
Some researchers believe that the use of microfluidics in the analysis of exosomes will help clinicians overcome the problem of heterogeneity in cancer cells.